Literature DB >> 31047016

Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease.

Aaron M Hein1, Julia J Scialla2, Daniel Edmonston2, Lauren B Cooper3, Adam D DeVore2, Robert J Mentz4.   

Abstract

Large randomized clinical trials (RCT) supporting guidelines for the management of heart failure with reduced ejection fraction (HFrEF) have typically excluded patients with advanced chronic kidney disease (CKD). Patients with concomitant advanced CKD and HFrEF experience poor cardiovascular outcomes and mortality relative to either disease in isolation and have been shown to consistently receive lower rates of HFrEF guideline-directed medical therapy (GDMT). This review evaluated recent evidence for the use of GDMT in patients with HFrEF and advanced CKD approaching dialysis from RCTs and observational cohorts. The authors also discuss the limitations and challenges inherent in the evidence for GDMT in this population, and offer guidance to clinicians for proper clinical use and future research directions.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; heart failure with reduced ejection fraction; heart failure management

Year:  2019        PMID： 31047016      PMCID： PMC6501813          DOI： 10.1016/j.jchf.2019.02.009

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


  57 in total

1.  Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Arthur J Moss; Scott McNitt; Wojciech Zareba; Mark L Andrews; W Jackson Hall; Henry Greenberg; Robert B Case
Journal:  Am J Cardiol       Date:  2006-06-19       Impact factor: 2.778

2.  Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis.

Authors:  Ali Ahmed; Thomas E Love; Xuemei Sui; Michael W Rich
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

3.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Authors:  G L Bakris; M R Weir
Journal:  Arch Intern Med       Date:  2000-03-13

4.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

5.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

6.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

7.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

8.  Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.

Authors:  Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; John J V McMurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick de Zeeuw; Stuart Pocock; Dirk J van Veldhuisen
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

9.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.

Authors:  Alan K Berger; Sue Duval; Connie Manske; Gabriela Vazquez; Cheryl Barber; Leslie Miller; Russell V Luepker
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

10.  Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study.

Authors:  Anna Kottgen; Stuart D Russell; Laura R Loehr; Ciprian M Crainiceanu; Wayne D Rosamond; Patricia P Chang; Lloyd E Chambless; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2007-03-07       Impact factor: 10.121
View more
  11 in total

1.  Beta-blockers in heart failure patients with severe chronic kidney disease-time for a randomized controlled trial?

Authors:  Rajiv Agarwal; Patrick Rossignol
Journal:  Nephrol Dial Transplant       Date:  2020-05-01       Impact factor: 5.992

2.  Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients.

Authors:  Shinsuke Takeuchi; Takashi Kohno; Ayumi Goda; Yasuyuki Shiraishi; Masataka Kawana; Mike Saji; Yuji Nagatomo; Yosuke Nishihata; Makoto Takei; Shintaro Nakano; Kyoko Soejima; Shun Kohsaka; Tsutomu Yoshikawa
Journal:  ESC Heart Fail       Date:  2022-05-13

Review 3.  Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.

Authors:  Iris E Beldhuis; Carolyn S P Lam; Jeffrey M Testani; Adriaan A Voors; Harriette G C Van Spall; Jozine M Ter Maaten; Kevin Damman
Journal:  Circulation       Date:  2022-02-28       Impact factor: 39.918

4.  Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate.

Authors:  Arjun Sinha; Clyde W Yancy; Ravi B Patel
Journal:  Eur J Heart Fail       Date:  2022-04-20       Impact factor: 17.349

Review 5.  Intersection Between Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Luke J Laffin; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

6.  Kidney Function and Outcomes in Patients Hospitalized With Heart Failure.

Authors:  Ravi B Patel; Gregg C Fonarow; Stephen J Greene; Shuaiqi Zhang; Brooke Alhanti; Adam D DeVore; Javed Butler; Paul A Heidenreich; Joanna C Huang; Michelle M Kittleson; Karen E Joynt Maddox; James J McDermott; Anjali Tiku Owens; Pamela N Peterson; Scott D Solomon; Orly Vardeny; Clyde W Yancy; Muthiah Vaduganathan
Journal:  J Am Coll Cardiol       Date:  2021-05-11       Impact factor: 27.203

7.  The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.

Authors:  Alberto Ortiz; Juan F Navarro-González; Julio Núñez; Rafael de la Espriella; Marta Cobo; Rafael Santamaría; Patricia de Sequera; Javier Díez
Journal:  Clin Kidney J       Date:  2021-12-23

8.  Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy.

Authors:  Niraj Varma; Robert C Bourge; Lynne Warner Stevenson; Maria Rosa Costanzo; David Shavelle; Philip B Adamson; Greg Ginn; John Henderson; William T Abraham
Journal:  J Am Heart Assoc       Date:  2021-02-25       Impact factor: 5.501

9.  Successful Treatment of Severe Heart Failure in Advanced Diabetic Kidney Disease Using Angiotensin-neprilysin Inhibitors (Sacubitril/Valsartan) - Report of Two Cases with Review of Options in Literature.

Authors:  Ratan Jha; Kiran K Mukku; Ambati K Rakesh; Sumeet Sinha
Journal:  Indian J Nephrol       Date:  2021-11-13

10.  Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients.

Authors:  Satoshi Shoji; Shun Kohsaka; Yasuyuki Shiraishi; Shogo Oishi; Mahoto Kato; Shigehito Shiota; Yasuko Takada; Atsushi Mizuno; Dai Yumino; Hiroyuki Yokoyama; Noboru Watanabe; Mitsuaki Isobe
Journal:  ESC Heart Fail       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.